We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Laboratory Corp. of America Holdings (LH - Free Report) is a leading independent clinical laboratory, whose offerings include a broad range of routine tests (including blood chemistry analysis, urinalyses, blood cell count, thyroid test, Pap tests and HIV tests) as well as specialty testing operations or esoteric testing.
Currently, LabCorp has a Zacks Rank #3 (Hold) but that could change following its fourth quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate is pegged at $2.37 per share over the last 30 days. LabCorp’s adjusted earnings per share of $2.45 is also up 14% on year-over-year basis.
Laboratory Corporation of America Holdings Price and EPS Surprise
Sales: LabCorp posted net revenues of $2.70 billion, which has missed the Zacks Consensus Estimate of $2.71 billion. The figure is up 13.2% on year-over-year basis.
Key Stats: Revenues from LabCorp Diagnostics segment increased 8.6% year over year to $1.82 billion in the fourth quarter, with total volume growth of 6.6%. Revenues from Covance Drug Development segment increased 23.8% to $886.1 million, owing to the acquisition of Chiltern, as well as organic growth and the benefit from foreign currency translation.
Major Factors: Management seemed to be upbeat about LabCorp’s impressive fourth quarter and full year results. Per management, the Diagnostics and Drug Development businesses each delivered excellent performance in the fourth quarter through a combination of strategic acquisitions, organic initiatives, and margin improvement. The company has also provided its 2018 guidance.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session
Check back later for our full write up on this LabCorp earnings report later!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
LabCorp (LH) Tops Q4 Earnings & Misses Revenue Estimates
Laboratory Corp. of America Holdings (LH - Free Report) is a leading independent clinical laboratory, whose offerings include a broad range of routine tests (including blood chemistry analysis, urinalyses, blood cell count, thyroid test, Pap tests and HIV tests) as well as specialty testing operations or esoteric testing.
Currently, LabCorp has a Zacks Rank #3 (Hold) but that could change following its fourth quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate is pegged at $2.37 per share over the last 30 days. LabCorp’s adjusted earnings per share of $2.45 is also up 14% on year-over-year basis.
Laboratory Corporation of America Holdings Price and EPS Surprise
Laboratory Corporation of America Holdings Price and EPS Surprise | Laboratory Corporation of America Holdings Quote
Sales: LabCorp posted net revenues of $2.70 billion, which has missed the Zacks Consensus Estimate of $2.71 billion. The figure is up 13.2% on year-over-year basis.
Key Stats: Revenues from LabCorp Diagnostics segment increased 8.6% year over year to $1.82 billion in the fourth quarter, with total volume growth of 6.6%. Revenues from Covance Drug Development segment increased 23.8% to $886.1 million, owing to the acquisition of Chiltern, as well as organic growth and the benefit from foreign currency translation.
Major Factors: Management seemed to be upbeat about LabCorp’s impressive fourth quarter and full year results. Per management, the Diagnostics and Drug Development businesses each delivered excellent performance in the fourth quarter through a combination of strategic acquisitions, organic initiatives, and margin improvement. The company has also provided its 2018 guidance.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session
Check back later for our full write up on this LabCorp earnings report later!
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>